Thomas F Freeman

US Patent:

20020178427, Nov 28, 2002

Filed:

May 25, 2001

Appl. No.:

09/865873

Inventors:

Cheng-Liang Ding - Cupertino CA, US
Thomas Freeman - Sunnyvale CA, US
Tzvi Ben-Tzur - Sunnyvale CA, US

International Classification:

G06F009/455

US Classification:

716/012000

Abstract:

A method and apparatus for shortening the time to emulation and user-friendliness of a hardware emulation system is disclosed that places adjustable delay elements at the inputs to each flip-flop in a design after the user's design has been compiled. The user selects the amount of delay to be programmed into the adjustable delay element.

US Patent:

20060047650, Mar 2, 2006

Filed:

Aug 24, 2005

Appl. No.:

11/211163

Inventors:

Thomas Freeman - Piedmont CA, US
Stephanie Mendelson - Alameda CA, US

International Classification:

G06F 17/30

US Classification:

707005000

Abstract:

A trainable record searcher is described. The trainable record searcher includes an iterative rules engine including at least an existing knowledge set, a plurality of rules, developed and entered to the iterative rules engine by at least one expert in at least one field of interest, a plurality of records for review by the iterative rules engine, where the plurality of rules are iteratively applied by the iterative rules engine to at least one training record. Also, the iterative application of the plurality of rules results in at least one rule modification in accordance with the existing knowledge set, where the plurality of rules, including the at least one rule modification, are applied by the iterative rules engine to a batch selected from the plurality of records to assess a compliance level for the batch of the plurality of records.

US Patent:

41006860, Jul 18, 1978

Filed:

Sep 6, 1977

Appl. No.:

5/830690

Inventors:

Thomas E. Sgarlato - Los Gatos CA
Gary A. Eston - Redwood City CA
Thomas E. Freeman - Redwood City CA

International Classification:

A63B 2100

US Classification:

36 29

Abstract:

A shoe sole construction is provided with a flexible bladder which is only partially filled with a non-compressible fluid. Preferably the fluid is water. The partially filled water bladder allows the water to flow from one portion of the bladder to other portions of the bladder during the walking cycle to provide proper support and maximum comfort and stability for the wearer of the shoe.

US Patent:

20210121436, Apr 29, 2021

Filed:

Oct 6, 2020

Appl. No.:

17/064576

Inventors:

- Palo Alto CA, US
- Naperville IL, US
Lisa Maria Lucia PHAM - San Mateo CA, US
Eunhye PARK - Oakland CA, US
Zhong ZHONG - Hingham MA, US
Guanyi HUANG - Fremont CA, US
Joseph C. WU - Palo Alto CA, US
Sidney Paul ELMER - Palo Alto CA, US
Viwat VISUTHIKRAISEE - Palo Alto CA, US
Eithon Michael G. CADAG - Seattle WA, US
Thomas Bernard FREEMAN - San Bruno CA, US
Pek Yee LUM - Palo Alto CA, US

Assignee:

Auransa Inc. - Palo Alto CA
SCT II LLC - Naperville IL

International Classification:

A61K 31/352
A61K 9/20
A61K 31/704
A61K 38/05
A61K 31/496
A61K 9/00
A61K 9/48
A61K 9/127
A61K 31/4439
A61K 31/136
A61K 31/4545
A61K 31/506
A61K 31/47
A61K 31/353
A61K 31/7048
A61K 31/517
A61P 35/00
A61K 38/00
A61K 45/06

Abstract:

This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

US Patent:

20200253920, Aug 13, 2020

Filed:

Jan 8, 2020

Appl. No.:

16/737849

Inventors:

- Palo Alto CA, US
- NAPERVILLE IL, US
Lisa Maria Lucia PHAM - San Mateo CA, US
Eunhye PARK - Oakland CA, US
Zhong ZHONG - Hingham MA, US
Guanyi HUANG - Fremont CA, US
Joseph C. WU - Palo Alto CA, US
Sidney Paul ELMER - Palo Alto CA, US
Viwat VISUTHIKRAISEE - Palo Alto CA, US
Eithon Michael G. CADAG - Seattle WA, US
Thomas Bernard FREEMAN - San Bruno CA, US
Pek Yee LUM - Palo Alto CA, US

Assignee:

Auransa Inc. - Palo Alto CA
SCT II LLC - NAPERVILLE IL

International Classification:

A61K 31/352
A61K 9/20
A61K 31/704
A61K 38/05
A61K 31/496
A61K 9/00
A61K 9/48
A61K 9/127
A61K 31/4439
A61K 31/136
A61K 31/4545
A61K 31/506
A61K 31/47
A61K 31/353
A61K 31/7048
A61K 31/517
A61P 35/00
A61K 38/00
A61K 45/06

Abstract:

This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

US Patent:

20190175544, Jun 13, 2019

Filed:

Feb 3, 2017

Appl. No.:

16/075569

Inventors:

- Palo Alto CA, US
- Redwood City CA, US
Lisa Maria Lucia Pham - San Mateo CA, US
Eunhye Park - Oakland CA, US
Zhong Zhong - Hingham MA, US
Guanyi Huang - Freemont CA, US
Joseph C. Wu - Palo Alto CA, US
Sidney Paul Elmer - Palo Alto CA, US
Viwat Visuthikraisee - Palo Alto CA, US
Eithon Michael G. Cadag - Seattle WA, US
Thomas Bernard Freeman - San Bruno CA, US
Pek Yee Lum - Palo Alto CA, US

Assignee:

SCT II LLC - Naperville IL
Auransa Inc. - Palo Alto CA

International Classification:

A61K 31/352
A61K 45/06
A61P 35/00
A61K 38/05
A61K 38/00

Abstract:

This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

US Patent:

20190177420, Jun 13, 2019

Filed:

Jul 18, 2018

Appl. No.:

16/038536

Inventors:

- Ingelheim am Rhein, DE
Thomas B. Freeman - San Bruno CA, US
Gerald Henery Nabozny - New Hope PA, US
Meera Ramanujam - New Hope PA, US
Paul Scholl - New Hope PA, US
Juergen Steffgen - Ulm, DE

Assignee:

Boehringer Ingelheim International GmbH - Ingelheim am Rhein

International Classification:

C07K 16/28

Abstract:

The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.

US Patent:

20170224654, Aug 10, 2017

Filed:

Feb 3, 2017

Appl. No.:

15/424743

Inventors:

- Redwood City CA, US
- Palo Alto CA, US
Lisa Maria Lucia Pham - San Mateo CA, US
Eunhye Park - Oakland CA, US
Zhong Zhong - Hingham MA, US
Guanyi Huang - Freemont CA, US
Joseph C. Wu - Palo Alto CA, US
Sidney Paul Elmer - Palo Alto CA, US
Viwat Visuthikraisee - Palo Alto CA, US
Eithon Michael G Cadag - Seattle WA, US
Thomas Bernard Freeman - San Bruno CA, US
Pek Yee Lum - Palo Alto CA, US

Assignee:

Stem Cell Theranostics, Inc. - Redwood City CA
Capella Biosciences, Inc. - Palo Alto CA

International Classification:

A61K 31/352
A61K 31/704
A61K 38/05
A61K 9/00
A61K 31/404
A61K 39/395
C07K 16/32
A61K 31/496
A61K 9/20
A61K 31/4412

Abstract:

This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).